

# Antikoagulační léčba u chronicky dialyzovaných pacientů s fibrilací síní – Společné stanovisko (expert opinion) České nefrologické společnosti a České kardiologické společnosti

## Literatura

### 1. Úvod do problematiky

- Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation* 2014;129:837–847.
- Kornej J, Borschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. *Circ Res* 2020;127: 4–20.
- Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001;285:2370–2375.
- Svensden JH, Diederichsen SZ, Hojberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. *Lancet* 2021;398:1507–1516.
- Chen LY, Sotoodehnia N, Bůžkova P, et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. *JAMA Intern Med* 2013;173: 29–35.
- Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation* 1998;98:946–952.
- Papanastasiou CA, Theochari CA, Zareifopoulos N, et al. Atrial fibrillation is associated with cognitive impairment, all-cause dementia, vascular dementia, and Alzheimer's disease: a systematic review and meta-analysis. *J Gen Intern Med* 2021;36:3122–3135.
- Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 2011;123:2946–2953.
- Watanabe H, Watanabe T, Sasaki S, et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. *Am Heart J* 2009;158:629–636.
- Bansal N, Fan D, Hsu Cy, et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. *Circulation* 2013;127:569–574.
- Massicotte-Azarniouch D, Kuwornu JP, Carrero JJ, et al. Incident atrial fibrillation and the risk of congestive heart failure, myocardial infarction, end-stage kidney disease, and mortality among patients with a decreased estimated GFR. *Am J Kidney Dis* 2018;71:191–199.
- Annual Data Report I USRDS n.d. Available at: <https://usrds-adr.niddk.nih.gov/2022/end-stage-renal-disease/1-incidence-prevalence-patient-characteristics-and-treatment-modalities> (accessed: May 2, 2023).
- Koplan BA, Winkelmayr WC, Costea AI, et al. Implantable loop recorder monitoring and the incidence of previously unrecognized atrial fibrillation in patients on hemodialysis. *Kidney Int Rep* 2022;7:189–199.
- Kazancıoğlu R. Risk factors for chronic kidney disease: an update. *Kidney Int Suppl* (2011) 2013;3:368–371.
- Akhtar Z, Leung LW, Kontogiannis C, et al. Arrhythmias in chronic kidney disease. *Eur Cardiol* 2022;17:e05.
- Ding WY, Gupta D, Wong CF, et al. Pathophysiology of atrial fibrillation and chronic kidney disease. *Cardiovasc Res* 2021;117:1046–1059.
- Everett TH, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. *Heart Rhythm* 2007;4(Suppl 3):S24–S27.
- Grabner A, Faul C. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy. *Curr Opin Nephrol Hypertens* 2016;25:314–324.
- Mehta R, Cai X, Lee J, et al. Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. *JAMA Cardiol* 2016;1:548–556.
- Malik J, Valerianova A, Pesickova SS, et al. Heart failure with preserved ejection fraction is the most frequent but commonly overlooked phenotype in patients on chronic hemodialysis. *Front Cardiovasc Med* 2023;10:1130618.
- Buiten MS, de Bie MK, Rotmans JI, et al. The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. *Heart* 2014;100:685–690.
- Correa S, Scovner KM, Tumlin JA, et al. Electrolyte changes in contemporary hemodialysis: a secondary analysis of the monitoring in dialysis study. *Kidney360* 2021;2:695–707.
- Hu A, Liu S, Montez-Rath ME, et al. Associations of serum and dialysate potassium concentrations with incident atrial fibrillation in a cohort study of older US persons initiating hemodialysis for kidney failure. *Kidney Int Rep* 2023;8:305–316.
- Wang HH, Hung SY, Sung JM, et al. Risk of stroke in long-term dialysis patients compared with the general population. *Am J Kidney Dis* 2014;63:604–611.
- Lutz J, Jurk K. Platelets in advanced chronic kidney disease: two sides of the coin. *Semin Thromb Hemost* 2020;46:342–356.
- Yu FP, Zhao YC, Gu B, et al. Chronic kidney disease and carotid atherosclerosis in patients with acute stroke. *Neurologist* 2015;20:23–26.
- Chelluboina B, Vemuganti R. Chronic kidney disease in the pathogenesis of acute ischemic stroke. *J Cereb Blood Flow Metab* 2019;39:1893–1905.
- Horl MP, Horl WH. Hemodialysis-associated hypertension: pathophysiology and therapy. *Am J Kidney Dis* 2002;39:227–244.
- Wang HH, Hung SY, Sung JM, et al. Risk of stroke in long-term dialysis patients compared with the general population. *Am J Kidney Dis* 2014;63:604–611.
- Power A, Chan K, Singh SK, et al. Appraising stroke risk in maintenance hemodialysis patients: a large single-center cohort study. *Am J Kidney Dis* 2012;59:249–257.
- Masson P, Webster AC, Hong M, et al. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. *Nephrol Dial Transplant* 2015;30:1162–1169.
- Cohen-Hagai K, Nacasch N, Rozenberg I, et al. Clinical outcomes of stroke in hemodialysis patients: a retrospective single-center study. *Int Urol Nephrol* 2019;51:1435–1441.
- Ovbiagele B, Schwamm LH, Smith EE, et al. Patterns of care quality and prognosis among hospitalized ischemic stroke patients with chronic kidney disease. *J Am Heart Assoc* 2014;3:e000905.

- Lee JG, Lee KB, Jang IM, et al. Low glomerular filtration rate increases hemorrhagic transformation in acute ischemic stroke. *Cerebrovasc Dis* 2013;35:53–59.
- Koplan BA, Winkelmayr WC, Costea AI, et al. Implantable loop recorder monitoring and the incidence of previously unrecognized atrial fibrillation in patients on hemodialysis. *Kidney Int Rep* 2022;7:189–199.
- Wald R, Dorian P, Harel Z. Benefits and risks of anticoagulation in dialysis patients with nonvalvular atrial fibrillation: navigating through darkness. *J Am Coll Cardiol* 2020;75:286–288.
- De Vriese AS, Heine G. Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. *Nephrol Dial Transplant* 2022;37:2072–2079.
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med* 2007;146:857–867.
- Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;365:981–992.
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;365:883–891.
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. *Circulation* 2024;149:e1–e156.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139–1151.
- Harel Z, Sholzberg M, Shah PS, et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. *J Am Soc Nephrol* 2014;25:431–442.
- Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian cardiovascular society/Canadian heart rhythm society comprehensive guidelines for the management of atrial fibrillation. *Can J Cardiol* 2020;36:1847–1948.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J* 2021;42:373–498.
- Yang F, Hellyer JA, Than C, et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. *Heart* 2017;103:818–826.
- Randhawa MS, Vishwanath R, Rai MP, et al. Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis. *JAMA Netw Open* 2020;3:e202175.
- Harel Z, Chertow GM, Shah PS, et al. Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis. *Can J Cardiol* 2017;33:737–746.
- Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. *Circulation* 2018;138:1519–1529.
- Hindley B, Lip GYH, McCloskey AP, Penson PE. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. *Expert Opin Drug Metab Toxicol* 2023;19:911–923.
- Mavranakas TA, Garlo K, Charytan DM. Apixaban versus No anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation. *Clin J Am Soc Nephrol* 2020;15:1146–1154.
- Sood MM, Larkina M, Thumma JR, et al. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. *Kidney Int* 2013;84:600–608.
- Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. *Kidney Int* 2010;77:1098–1106.

## 2. Riziková stratifikace

- Zamberg I, Assouline-Reinmann M, Carrera E, et al. Epidemiology, thrombolytic management, and outcomes of acute stroke among patients with chronic kidney disease: a systematic review and meta-analysis. *Nephrol Dial Transplant* 2022;37:1289–1301.
- Sood MM, Larkina M, Thumma JR, et al. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. *Kidney Int* 2013;84:600–608.
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2024;45:3314–3414.
- Murray AM, Seliger S, Lakshminarayan K, et al. Incidence of stroke before and after dialysis initiation in older patients. *J Am Soc Nephrol* 2013;24:1166–1173.
- Madken, M. et al. Development and Validation of a Predictive Risk Algorithm for Bleeding in Individuals on Long-term Hemodialysis: An International Prospective Cohort Study (BLEED-HD). *Can J Kidney Health Dis* 2023;10:20543581231169610.
- Kirchhof, P. et al. Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. *N Engl J Med* 2023;389:1167–1179.
- Healey JS, Lopes RD, Granger CB, et al. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. *N Engl J Med* 2024;390:107–117.
- Huang C, Li L, Liu W, et al. Time to benefit and harm of direct oral anticoagulants in device-detected atrial fibrillation: A pooled analysis of the NOAH-AFNET 6 and ARTESIA trials. *Heart Rhythm* 2024;21:2422–2428.
- Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. *Kidney Int* 2010;77:1098–1106.

## 3. Možnosti prevence

### ■ Warfarin

- Wheeler DS, Giugliano RP, Rangaswami J. Anticoagulation-related nephropathy. *J Thromb Haemost* 2016;14:461–467.
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2024;45:3314–3414.
- Randhawa MS, Vishwanath R, Rai MP, et al. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2020;3:e202175.
- Jain N, Reilly RF. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. *Clin J Am Soc Nephrol* 2019;14:278–287.
- Chang JJ. Calciphylaxis: Diagnosis, Pathogenesis, and Treatment. *Adv Skin Wound Care* 2019;32:205–215.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2021;42:373–498.

### ■ Dabigatran

- Chen S, Liao D, Yang M, Wang S. Anticoagulant-related nephropathy induced by direct-acting oral anticoagulants: Clinical characteristics, treatments and outcomes. *Thromb Res* 2023;222:20–23.

### ■ Apixaban

- Correction. Kuno T, Takagi H, Ando T, Sugiyama T, Miyashita S, Valentin N, Shimada YJ, Kodaira M, Numasawa Y, Briasoulis A, Burger A, Bangalore S. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. *J Am Coll Cardiol* 2020;75:842.
- Reinecke H, Engelbertz C, Bauersachs R, et al. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic

Hemodialysis: The AXADIA-AFNET 8 Study. *Circulation* 2023;147:296–309.

Pokorney SD, Chertow GM, Al-Khalidi HR, et al. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. *Circulation* 2022;146:1735–1745.

Otero A, Rosselló-Palmer E, Codina S, et al. Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients. *Kidney Int Rep* 2024;9:2798–2802.

Mavrakanas TA, Samer CF, Nessim SJ, et al. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. *J Am Soc Nephrol* 2017;28:2241–2248.

### ■ Rivaroxaban

De Vriese AS, Caluwé R, Van Der Meersch H, et al. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. *J Am Soc Nephrol* 2021;32:1474–1483.

De Vriese AS, Caluwé R, Pyfferoen L, et al. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. *J Am Soc Nephrol* 2020;31:186–196.

### ■ Nízkomolekulární hepariny (LMWH) a heparin

Santos A, Macías N, Vega A, et al. Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration. *Clin Kidney J* 2021;14:1120–1125.

Brophy DF, Martin EJ, Gehr TWB, et al. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. *J Thromb Haemost* 2006;4:372–376.

Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. *Am Heart J* 2002;143:753–759.

### ■ Fondaparinux

Mahieu E, Claes K, Jacquemin M, et al. Anticoagulation With Fondaparinux for Hemodiafiltration in Patients With Heparin-Induced Thrombocytopenia: Dose-Finding Study and Safety Evaluation. *Artif Organs* 2013;37:482–487.

Cope J, Bushwitz J, An G, et al. Clinical Experience With Prophylactic Fondaparinux in Critically Ill Patients With Moderate to Severe Renal Impairment or Renal Failure Requiring Renal Replacement Therapy. *Ann Pharmacother* 2015;49:270–277.

### ■ Kyselina acetylsalicylová (ASA) a inhibitory P2Y<sub>12</sub> – thienopyridiny (clopidogrel, prasugrel) a non-thienopyridiny (ticagrelor)

Wang Q, Xie X, Xu G. The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis. *BMC Nephrol* 2020;21:106.

Van Walraven C, Hart RG, Singer DE, et al. Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation: An Individual Patient Meta-analysis. *JAMA* 2002;288:2441–2448.

Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2024;45:3314–3414.

Tanios BY, Itani HS, Zimmerman DL. Clopidogrel Use in End-Stage Kidney Disease. *Semin Dial* 2015;28:276–281.

Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2016;37:267–315.

Qamar A, Bhatt DL. Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease. *Circulation* 2016;133:1512–1515.

Ibanez B, James S. The 2017 ESC STEMI Guidelines. *Eur Heart J* 2018;39:79–82.

Chenna VSH, Anam H, Hassan M, et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis. *Cureus* 2023;15:e40211

Edfors R, Sahlén A, Szummer K, et al. Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function. *Heart* 2018;104:1575–1582.

Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;324:71–86.

Bonello L, Angiolillo DJ, Aradi D, Sibbing D. P2Y<sub>12</sub>-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes: Review of the Current Evidence. *Circulation* 2018;138:1582–1596.

Baigent C, Landray M, Leaper et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. *Am J Kidney Dis* 2005;45:473–484.

### ■ LAA

Genovesi S, Porcu L, Rebora P, et al. Long-term safety and efficacy of left atrial appendage occlusion in dialysis patients with atrial fibrillation: a multi-center, prospective, open label, observational study. *Clin Kidney J* 2023;16:2683–2692.

### ■ ASA a shunt

Schmidli J, Widmer MK, Basile C, et al. Editor's Choice – Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg* 2018;55:757–818.

Gallieni M, Hollenbeck M, Inston N, et al. Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults. *Nephrol Dial Transplant* 2019;34(Suppl. 2):ii1–ii42.

Ebertz DP, Bose S, De Valle A, et al. Single or Dual Antiplatelet Therapy Improves One-Year Arteriovenous Graft Patency and Overall Survival. *Ann Vasc Surg* 2025;111:367–385.

### ■ Čekatelé na transplantaci

Santoro F, Casanova A, Simone S, et al. Immunosuppressive therapy and oral anticoagulation in kidney transplant recipients: Direct oral anticoagulants versus vitamin-k antagonists. *Eur J Intern Med* 2024;119:71–77.

Roca Mora MM, Milani Reis A, Piazza Tavares F, et al. Safety and efficacy of direct oral anticoagulants in kidney transplant recipients: A systematic review and meta-analysis. *Transplant Rev (Orlando)* 2025;39:100899.

Afsar B, Afsar RE, Caliskan Y, Lentene KL. Use of Direct Anticoagulants in Kidney Transplant Recipients: Review of the Current Evidence and Emerging Perspectives. *Am J Cardiovasc Drugs* 2025;25:135–146.

### ■ Výhled do budoucna

Ruff CT, Patel SM, Giugliano RP, et al. Abelimab versus Rivaroxaban in Patients with Atrial Fibrillation. *N Engl J Med* 2025;392:361–371.

Piccini JP, Patel MR, Steffel J, et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. *N Engl J Med* 2025;392:23–32.

Patel SM, Giugliano RP, Ruff CT. Factor XI Inhibition for Atrial Fibrillation: Where Do We Stand? *Circulation* 2025;151:1433–1435.

Kumar V, Ilkhanoff L. Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors. *Front Cardiovasc Med* 2024;11:1352734.

Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. *N Engl J Med* 2013;369:2093–2104.